Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response. The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation. LPI (LP Information)' newest research report, the “Allergy Immunotherapies Industry Forecast” looks at past sales and reviews total world Allergy Immunotherapies sales in 2022, providing a comprehensive analysis by region and market sector of projected Allergy Immunotherapies sales for 2023 through 2029. With Allergy Immunotherapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Allergy Immunotherapies industry. This Insight Report provides a comprehensive analysis of the global Allergy Immunotherapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Allergy Immunotherapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Allergy Immunotherapies market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Allergy Immunotherapies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Allergy Immunotherapies. The global Allergy Immunotherapies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029. In Southeast Asia Allergy Immunotherapies key players include ALK, Stallergenes, etc. Southeast Asia top two manufacturers hold a share about 65%. Singapore is the largest market, with a share over 30%, followed by Thailand and Malaysia, both have a share about 35 percent. In terms of product, Subcutaneous Immunotherapy is the largest segment, with a share about 43%. And in terms of application, the largest application is Allergic Rhinitis, followed by Allergic Asthma, etc. This report presents a comprehensive overview, market shares, and growth opportunities of Allergy Immunotherapies market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Subcutaneous Immunotherapy Sublingual Immunotherapy Segmentation by application Allergic Rhinitis Allergic Asthma Other This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. ALK Stallergenes HAL
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Allergy Immunotherapies Market Size 2018-2029 2.1.2
